506 Pegylated interferon alpha-2b monotherapy and in combination with ribavirin in chronic hepatitis delta

Niro, G.A.; Ciancio, Angela; Gaeta, G.B.; Marrone, Aldo; Olivero, A.; Stanzione, Maria; Stornaiuolo, Gianfranca; Smedile, Antonina; Andriulli, Angelo; Rizzetto, M.

doi:10.1016/s0168-8278(06)80506-4

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a study assessing PegIFN-2a monotherapy versus PegIFN-2a in combination with ribavirin, monotherapy resulted in only 20% of patients achieving sustained HDV clearance. 84 Adverse events (AE) were common on therapy, with dose modifications required for 50% of patients on PegIFN-2a monotherapy. 84 Likewise, relapses are frequent; in a 5-year follow-up of a trial of PegIFN-2a with or without adefovir dipivoxil, 56% of patients with HDV infection who had achieved sustained virologic response had a virologic relapse after therapy was discontinued.…”

Section: Therapymentioning

confidence: 99%

Hepatitis Delta Infection: A Clinical Review

Pearlman

2023

Semin Liver Dis

View full text Add to dashboard Cite

First discovered over 40 years ago, the hepatitis delta virus (HDV) is a unique RNA virus, requiring hepatitis B virus (HBV) antigens for its assembly, replication, and transmission. HBV and HDV can be acquired at the same time (coinfection) or HDV infection can occur in persons with chronic HBV (superinfection). Screening guidelines for HDV are inconsistent. While some guidelines recommend universal screening for all people with HBV, others recommend risk-based screening. Estimates of the global HDV prevalence range from 4.5% to 14.6% among persons with HBV; thus, there may be up to 72 million individuals with HDV worldwide. HDV is the most severe form of viral hepatitis. Compared to HBV monoinfection, HDV coinfection increases the risk of cirrhosis, hepatocellular carcinoma, hepatic decompensation, mortality, and necessity for liver transplant. Despite the severity of HDV, there are few treatment options. Pegylated interferon (off-label use) has long been the only available treatment, although bulevirtide is conditionally approved in some European countries. There are many potential treatments in development, but as yet, there are few effective and safe therapies for HDV infection. In conclusion, given the severity of HDV disease and the paucity of treatments, there is a great unmet need for HDV therapies.

show abstract

Section: Therapymentioning

confidence: 99%

Hepatitis Delta Infection: A Clinical Review

Pearlman

2023

Semin Liver Dis

View full text Add to dashboard Cite

show abstract

Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV–HIV International Panel

Soriano¹,

Puoti

Sulkowski

et al. 2007

Aids

306

268

View full text Add to dashboard Cite

Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel

Soriano¹,

Puoti

Peters

et al. 2008

Aids

152

134

View full text Add to dashboard Cite

Nearly 10% of the estimated 36 million people having HIV worldwide suffer from chronic hepatitis B virus (HBV) infection. The advent of new antiviral agents against HBV and the recent availability of improved molecular diagnostic tools have revolutioned the management of HIV/HBV coinfected patients. The present study represents an update of the current knowledge about HBV/HIV coinfection and an intent to provide practical advise about how to give the best care to HIV-infected persons with chronic hepatitis B.

show abstract

506 Pegylated interferon alpha-2b monotherapy and in combination with ribavirin in chronic hepatitis delta

Cited by 3 publications

References 0 publications

Hepatitis Delta Infection: A Clinical Review

Hepatitis Delta Infection: A Clinical Review

Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV–HIV International Panel

Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel

Contact Info

Product

Resources

About